ACSM Position Stand: The Use of Blood Doping as an Ergogenic Aid
Authors:
- Michael N. Ph.D. SawkaMSMichael N. Ph.D. Sawka
- Michael J. JoynerMJMichael J. Joyner
- D. S. Ph.D. MilesDMD. S. Ph.D. Miles
- Robert J. Ph.D. RobertsonRRRobert J. Ph.D. Robertson
- Lawrence L. Ph.D. SprietLSLawrence L. Ph.D. Spriet
- Andrew J. Ph.D. YoungAYAndrew J. Ph.D. Young
- 1 October 1996
- journal article
- acsm position-stand
- Published by Wolters Kluwer Health in Medicine & Science in Sports & Exercise
- Vol. 28 (10) , 127-134
Abstract
Blood doping has been achieved by either infusing red blood cells or by administering the drug erythropoietin to artificially increase red blood cell mass. Blood doping can improve an athlete's ability to perform submaximal and maximal endurance exercise. In addition, blood doping can help reduce physiologic strain during exercise in the heat and perhaps at altitude. Conversely, blood doping is associated with risks that can be serious and impair athletic performance. These known risks are amplified by improper medical controls, as well as the interaction between dehydration with exercise and environmental stress. Finally, the medical risks associated with blood doping have been estimated from carefully controlled research studies, and the medically unsupervised use of blood doping will increase these risks. It is the position of the American College of Sports Medicine that any blood doping procedure used in an attempt to improve athletic performance is unethical, unfair, and exposes the athlete to unwarranted and potentially serious health risks.Keywords
This publication has 50 references indexed in Scilit:
- Hematological Indices of Erythropoietin Administration in AthletesInternational Journal of Sports Medicine, 1993
- Effect of Erythropoietin Treatment on Physical Exercise Capacity and on Renal Function in Predialytic Uremic PatientsNephron, 1992
- Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy menJournal of Internal Medicine, 1991
- Hypertension as a Possible Complication of Recombinant Human Erythropoietin Therapy1991
- Improved Physical Performance after Treatment of Renal Anemia with Recombinant Human ErythropoietinNephron, 1991
- Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.BMJ, 1990
- Effect of Reinfusion of Autologous Blood on Exercise Performance in Cross-country SkiersInternational Journal of Sports Medicine, 1987
- Detection of Autologous Blood Transfusions in Cross-Country SkiersInternational Journal of Sports Medicine, 1987
- Effects of anaemia and stepwise‐induced polycythaemia on maximal aerobic power in individuals with high and low haemoglobin concentrationsActa Physiologica Scandinavica, 1987
- Effect of induced erythrocythemia on aerobic work capacityJournal of Applied Physiology, 1980